ERBB2 and neoplasm: This combination is presents a viable option for patients with low tumor burden as an active anti-HER2 therapy, while T-DXd monotherapy has shown some antitumor activity in HER2-positive mCRC patients according to the phase II clinical trial (Destiny-CRC01) [166].